

## Curriculum vitae

Capone Emily May, 13th 1986 23, Via Alcide De Gasperi; 73020 Cavallino (LE) Italy; Mobile: +39 3288416337

Email: emily.capone@unich.it

### Education:

January 2013 – December 2015: PhD in Molecular and Clinical Oncology

July 2011: Passed the government exam and licensed as a profession biologist

December 2008 – April 2011: Master Degree in Industrial and Pharmaceutical Biotechnology passing grade of 110/110 with honours; University of Salento, Lecce (Italy)

September 2005 – December 2008: Bachelor degree in Biotechnology passing grade of 110/110 with honours; University of Salento, Lecce (Italy)

September 2000 – July 2005: Science high school – Grades 91/100

### Research Experience:

February 2017-ongoing: AIRC fellowship on the project named: "Study of the antitumor activity of humanized anti-HER-3 antibody (EV20) conjugated to potent cytotoxics in mono therapy and in combination with tyrosine kinase and BRAF inhibitors".

November 2012 – December 2015: PhD Student University G.D'Annunzio Chieti-Pescara

May 2010 – April 2011: Undergraduate Trainee at Institute of Oncology "Giovanni Paolo II"

### Technical skills and competence:

Languages skills: Italian: Mother tongue; English: Independent user

Job-related skills: Cell culture, Restriction Enzyme Digestion and Gel electrophoresis, DNA fragment purification and ligase reaction; Mini-prep and Maxi-prep; Transformation; Cell culture and transfection; Total and Nucleo/citosol protein Extraction; Immunoprecipitation; Western-blot; DNA/RNA extraction; PCR; MTT and other proliferation assays; ELISA; Flow Citometry; Confocal microscopy; in vivo experiments.

### Relevant publications:

1. Ponziani S. et al. *Antibody-drug conjugates: The new frontier of chemotherapy*. International Journal of Molecular Sciences Volume 21, Issue 15, 1 August 2020, Article number 5510, Pages 1-28.
2. Bibbo' S, et al. *Repurposing a psychoactive drug for children with cancer: p27Kip1-dependent inhibition of metastatic neuroblastomas by Prozac*. Oncogenesis. 2020 Jan 2;9(1):3. doi: 10.1038/s41389-019-0186-3.
- Gandullo-Sánchez L, et al. *HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies*. EMBO Mol Med. 2020;12(5):e11498. doi:10.15252/emmm.201911498.
4. Casari I, et al. *Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation*. Cancers (Basel). 2019 Oct 31;11(11). pii: E1695. doi: 10.3390/cancers11111695.
5. Adamska A, et al. *Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer*. J Exp Clin Cancer Res. 2019 Aug 5;38(1):312. doi: 10.1186/s13046-019-1308-7.
6. Emmanouilidi A, et al. *Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer*. J Exp Clin Cancer Res. 2019 May 14;38(1):191. doi: 10.1186/s13046-019-1191-2
7. Adamska A, et al. *ABCC3 is a novel target for the treatment of pancreatic cancer*. Adv Biol Regul. 2019 Apr 24. pii: S2212-4926(19)30036-3. doi: 10.1016/j.jbior.2019.04.004.
8. Giansanti, F., et al., *Secreted Gal-3BP is a novel promising target for non-internalizing Antibody-Drug Conjugates*. J Control Release, 2018. **294**: p. 176-184.
9. Capone, E., et al., *EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma*. J Control Release, 2018. **277**: p. 48-56.
10. Capone, E., et al., *Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma*. Oncotarget, 2017. **8**(36): p. 60368-60377.
11. Capone, E., et al., *EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma*. Oncotarget, 2017. **8**(56): p. 95412-95424.

12. Prasetyanti, P.R., et al., *ErbB-3 activation by NRG-1beta sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs)*. Oncotarget, 2015. **6**(19): p. 16902-11.
13. De Cola, A., et al., *miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance*. Cell Death Dis, 2015. **6**: p. e1823.
14. Capone, E., P.R. Prasetyanti, and G. Sala, *HER-3: hub for escape mechanisms*. Aging (Albany NY), 2015. **7**(11): p. 899-900.
15. Ghasemi, R., et al., *Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer*. Oncogenesis, 2014. **3**: p. e117.
16. Sala, G., et al., *EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo*. Transl Oncol, 2013. **6**(6): p. 676-84.

## Patents

- *"Endosialin Binding antibody"* US 2019 / 0160180 A1. Inventors : Stefano Iacobelli, Annalisa Di Risio, Enza Piccolo, Gianluca Sala, Emily Capone. Pub . Date : May 30 , 2019.
- *"LGALS3BP antibody-drug-conjugate and its use for the treatment of cancer"*. WO 2019/197651 A1. Inventors: Emily Capone, Francesco Giansanti, Rodolfo Ippoliti, Roberta Gentile, Stefano Iacobelli, Enza Piccolo, Sara Ponziani, Gianluca Sala. Date : October 17 , 2019.